Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide by Wilson, Sarah M. & Khanna, Rajesh
Specific binding of lacosamide to collapsin response mediator 
protein 2 (CRMP2) and direct impairment of its canonical 
function: implications for the therapeutic potential of lacosamide
Sarah M. Wilson1 and Rajesh Khanna1,2,*
1Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, 
Indianapolis, IN 46202, USA
2Department of Pharmacology and Neuroscience Graduate Interdisciplinary Program, College of 
Medicine, University of Arizona, Tucson, AZ 85742
Abstract
The novel anti-epileptic drug lacosamide (LCM; SPM927, Vimpat®) has been heralded as having 
a dual-mode of action through interactions with both the voltage-gated sodium channel and the 
neurite outgrowth-promoting collapsin response mediator protein 2 (CRMP2). Lacosamide’s 
ability to dampen neuronal excitability through the voltage-gated sodium channel likely underlies 
its efficacy in attenuating the symptoms of epilepsy (i.e. seizures). While the role of CRMP2 in 
epilepsy has not been well-studied, given the proposed involvement of circuit reorganization in 
epileptogenesis, the ability of lacosamide to alter CRMP2 function may prove disease-modifying. 
Recently, however, the validity of lacosamide’s interaction with CRMP2 has come under scrutiny. 
In this review, we address the contradictory reports concerning the binding of lacosamide to 
CRMP2, as well as, the ability of lacosamide to directly impact CRMP2 function. Additionally, 
we address similarly contradicting reports regarding the potential disease-modifying effect of 
lacosamide on the development and progression of epilepsy. As the vast majority of anti-epileptic 
drugs influence only the symptoms of epilepsy, the ability to hinder disease progression would be 
a major breakthrough in efforts to cure or prevent this debilitating syndrome.
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Introduction: Lacosamide as a novel anti-epileptic
Lacosamide (LCM; SPM927, Vimpat®) (R-N-benzyl 2-acetamido-3-methoxypropionamide) 
is a first in class antiepileptic drug (AED) approved by the United States Food and Drug 
Administration and the European Medicines Agency for adjunctive treatment of partial-
onset epilepsy with or without secondary generalization in adults (for review see [1]). 
Lacosamide was first identified as the lead compound in a class of functionalized amino 
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acids demonstrating antiepileptic properties in the maximal electroshock model [2,3]. 
Lacosamide reduced seizure activity in the genetically susceptible Frings mouse as well as 
the hippocampal kindled rat [4]. Additionally lacosamide demonstrated antiepileptic 
potential in the 6 Hz psychomotor seizure model of partial epilepsy [5,6]. The efficacy of 
lacosamide in these diverse models separated it from currently available anti-epileptic drugs. 
However, lacosamide was unable to ameliorate tonic-clonic seizures associated with 
subcutaneous administration of picrotoxin, bicuculline, or pentylenetetrazole [6]. Phase III 
clinical trials evaluated the ability of lacosamide to control partial-onset seizures when used 
in conjunction with 1–3 other AEDs (for review see [7]). The proportion of subjects who 
reported a ≥50% seizure reduction rate increased from 23% with placebo to 40% with 400 
mg lacosamide treatment. Unfortunately, seizure freedom remained out of reach, with only 5 
of 107 subjects reporting total loss of seizure activity within the 28 day trial period [8]. 
While improvement was observed with the addition of lacosamide treatment, results were 
modest. However, the advantage of lacosamide lies within its low potential for drug-drug 
interactions, allowing it to be combined with almost every class of AED as a concomitant 
treatment option [7]. While pharmacokinetic studies report a limited impact of age and 
gender on lacosamide serum levels [9], no influence on efficacy was identified in clinical 
trials [10]. Lacosamide treatment was also associated with low incidence of severe adverse 
advents, with the most commonly reported side effects being dizziness, headache, nausea, 
and diplopia [11] (For an in-depth review of the clinical value and limitations of lacosamide 
please see [1]).
Mechanism of action
Despite its success in both pre-clinical and clinical studies, the mechanism by which 
lacosamide alleviated seizure activity remained unknown [5]. Radioligand displacement 
studies attempted to identify a target for lacosamide within the central nervous system. 
While the ability of lacosamide to weakly displace H3-Batrachotoxin indicated some level of 
binding to voltage-gated sodium channels (VGSCs), lacosamide treatment did not affect 
steady-state gating kinetics or current density [12]. It was ultimately determined that 
lacosamide reduces excitability through selective enhancement of VGSC slow inactivation 
[13]. It was hypothesized that this unique method of action would allow for discrimination 
between steady-state and aberrantly increased levels of firing. Lacosamide derivatives were 
employed as affinity baits in an attempt to identify any additional targets within the central 
nervous system [14–16]. The results of these studies suggested that, aside from the VGSC, 
lacosamide may also target collapsin response mediator protein 2 (CRMP2). CRMP2, also 
known as DPYSL2/DRP2, Unc-33, Ulip, or TUC2, is an intracellular phosphoprotein first 
identified for its role in regulating growth cone extension/retraction [17,18]. The canonical 
roles of CRMP2 include its involvement in neurite outgrowth, axon/dendrite specification, 
neuronal polarity, progenitor proliferation, and radial migration (for review see [19,20,18]). 
Central to many of these functions is the ability of CRMP2 to regulate microtubule 
dynamics. Through interactions with the anterograde motor protein kinesin, CRMP2 aids in 
the transport of tubulin dimers from the soma to distal projections [21]. Additionally, 
CRMP2 stabilizes the growing end of the microtubule and promotes the inherent GTPase 
activity of tubulin [22]. The aforementioned processes are governed by the phosphorylation 
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state of CRMP2, whereby phosphorylation by GSK3β, Cdk5, ROCK, CaMKII, or FYN 
kinase renders CRMP2 inactive, promoting neurite retraction and growth cone collapse [23–
31]. Recent work has uncovered a multitude of additional roles for CRMP2 in neurons 
including neurodegeneration, cell death, and trafficking control [32–39]. Indeed, the 
CRMP2 interactome has expanded to include proteins involved in microtubule dynamics, 
synaptic assembly, vesicle recycling and endocytosis, neurotransmitter release, and calcium 
channel regulation (for review see [40]). Given the number and wide variety of functions 
and interacting partners, it is not surprising that CRMP2 has been implicated in numerous 
disease states. Therefore, the potential impact of lacosamide interacting with CRMP2 is 
substantial.
Does lacosamide have a dual mode of action?
Despite the original evidence supporting CRMP2 as a target of lacosamide, the validity of 
the interaction remains controversial. The first evidence supporting the interaction can be 
found in the aforementioned preclinical report published by Beyreuther and colleagues [14]. 
Direct evidence supporting their claims that CRMP2 is a target of lacosamide can be found 
within a patent application filed by three of the authors: Beyreuther, Stohr, and Freitag [41]. 
The most convincing data within the application are the radioligand binding studies where 
they demonstrated competitive and specific binding of [14C]-lacosamide to crude fractions 
isolated from Xenopus oocytes transfected with CRMP2, as well as rat brain membranes. 
These studies reported a Kd-value lower than 5 μM. Importantly, radioligand binding could 
be competed off with an excess of cold, unlabeled lacosamide. Additionally, no specific 
binding was reported from control Oocyte fractions not containing CRMP2. Based on these 
results, along with others supporting the interaction of CRMP2 and lacosamide, the 
application states the following: “CRMP2 is therefore regarded as a target of lacosamide in 
the nervous system in epilepsy, pain, essential tremor, dyskinesias, amyotrophic lateral 
sclerosis, schizophrenia, and other disease conditions” [41]. Soon after, Park and colleagues 
demonstrated affinity-bait capture of CRMP2 by lacosamide in two separate reports [15,16]. 
Affinity-bait methods aid in the identification of unknown protein binding partners (Figure 
1). In these experiments, two additional moieties are added to the ligand in question (i.e. 
lacosamide), an “affinity bait moiety” (AB) and a “chemical reporter moiety” (CR). Upon 
binding of the ligand to a potential target, the AB moiety covalently modifies the target 
creating an irreversible interaction. Binding partners can be identified by in-gel fluorescence 
of the CR moiety. The addition of the AB and CR groups can potentially modify the ligand; 
therefore, it is imperative for the final product to mimic the original ligand in functionality. 
Lacosamide agents containing the AB and CR moieties (lacosamide AB-CR) were 
determined to provide antiepileptic relief in the MES model similar to that of the parent 
compound [15,16]. Soluble mouse brain lysates were incubated with 5 μM of the lacosamide 
AB-CR compound for 30 minutes at room temperature and separated using electrophoresis. 
Proteins captured by the lacosamide AB-CR compound were visualized by in-gel 
fluorescence of the CR moiety. Reactivity was observed around 62 kDa, which correlates to 
the size of CRMP2. CRMP2 immunoreactivity was also confirmed at 62 kDa from the 
samples. To confirm the identity of the 62 kDa protein captured by the affinity bait 
experiment, the experiment was repeated using a biotinylated lacosamide AB-CR 
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compound. Lacosamide AB-CR/target protein complexes could then be isolated using 
streptavidin precipitation. Mass spectrometry of the gel-excised 62 kDa band captured by 
the AB-CR compound confirmed its identity to be CRMP2. Importantly, the capture of 
CRMP2 by lacosamide AB-CR could be prevented in a dose-dependent manner by excesses 
of the original lacosamide compound [16]. Other potential targets have since been identified 
using this method, such as 14-3-3 [42]. However, the impact of this interaction has not yet 
been determined.
A 2010 report by our laboratory verified the ability to capture CRMP2 with lacosamide 
affinity bait compounds [43]. Furthermore, in silico docking was used to identify putative 
binding sites for lacosamide within the CRMP2 protein. The technique uses the known 
structure of the target protein (CRMP2) to predict the structure of the intermolecular 
complex when bound to a ligand (lacosamide) (for review see [44]). A total of 100 runs 
were carried out over the surface of the CRMP2 protein to yield five pockets capable of 
coordinating lacosamide binding. Interestingly, it was observed that CRMP2 expression 
levels could influence the ability of lacosamide to transition voltage-gated sodium channels 
to the slow-inactivated state in a neuronal cell line. Site-directed mutagenesis of key 
residues within the previously identified binding pockets on CRMP2 prevented the impact 
of CRMP2-overexpression on modulation of VGSC slow inactivation by lacosamide.
While evidence suggested that CRMP2 might be a target of lacosamide, it was unclear if this 
interaction would impact the function of CRMP2. Calcium dysregulation has been suggested 
to play a large role in the pathophysiology of various epilepsies [45]. As CRMP2 is a 
positive regulator of N-type calcium channels, our laboratory sought to determine if acute or 
chronic lacosamide treatment could impact calcium channel currents. Primary cultured 
hippocampal neurons were treated with 300 μM lacosamide for 0.5–24 hours. Whole cell 
patch clamp recordings revealed that neither acute nor chronic treatment altered current 
density or kinetics of activation or inactivation [46]. As the L-type calcium channel currents 
were inhibited by the presence of nifedipine, currents predominantly represented calcium 
carried through N-type channels, with a small percentage attributed to P/Q-type channels at 
this age in culture [47]. Consistent with previous findings, overexpression of CRMP2 led to 
an ~60% increase in current density, which was not altered by the presence of lacosamide. 
We then investigated if lacosamide could impact the canonical role of CRMP2 in neurite 
outgrowth. Sholl analysis was used to measure neurite length and complexity in primary 
cultured cortical neurons. This technique measures the number of neurites crossing 
concentric circles (denoted as intersections or branch points) at various radial distances from 
the cell soma [48]. This consecutive-circles (cumulative intersection) analysis identifies 
dendritic geometry, ramification abundance, and branching patterns. Overnight application 
of 300 μM lacosamide led to a ~30% decrease in neurite outgrowth, which could not be 
replicated with the application of other sodium channel inhibitors [49]. Specificity of this 
outcome was confirmed, as lacosamide was unable to further reduce outgrowth following 
siRNA knockdown of CRMP2. Concentration-response curves yielded an IC50 of ~25 μM, a 
concentration which was unable to alter sodium channel slow inactivation, suggesting that 
lacosamide may alter CRMP2 function at concentrations previously considered to be sub-
therapeutic. However, the distinct mechanism by which lacosamide impaired CRMP2-
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mediated neurite outgrowth remained unclear. CRMP2 promotes outgrowth through two 
separate and distinct mechanisms: (1) linking tubulin dimers to the motor protein kinesin to 
aid in anterograde transport [21] and (2) enhancing the intrinsic GTPase activity of tubulin 
[22]. The ability of CRMP2 to co-immunoprecipitate tubulin was not affected by upwards of 
300 μM lacosamide [49]. Tubulin polymerization, as measured by a turbidimetric assay, is 
greatly increased in the presence of purified CRMP2 protein. While high concentrations of 
lacosamide (300 μM) did not alter basal levels of tubulin polymerization, the addition of 3 
μM lacosamide was sufficient to prevent increases in polymerization by CRMP2. 
Previously, our laboratory had created a mutant CRMP2 protein (CRMP25ALA) in which 5 
residues, identified by in silico docking to be the most critical for lacosamide binding, had 
been mutated to alanines. Lacosamide was unable to block the enhancement of tubulin 
polymerization by CRMP25ALA. Based on these results, we concluded that lacosamide 
reduces CRMP2-mediated neurite outgrowth by selectively impairing the ability of CRMP2 
to enhance tubulin polymerization.
The aforementioned findings supporting a direct interaction between lacosamide and 
CRMP2 are in contrast to a 2012 report by Wolff and colleagues [50]. Previous radioligand 
binding studies reported a Kd of ~5 μM; however these employed [14C] lacosamide which 
was reported to have low specific radioactivity, limiting further binding studies. Therefore, 
Wolff and colleagues used [3H] lacosamide, whose specific activity was 1000 fold higher 
than that of [14C] lacosamide. No specific binding was observed in fractions taken from rat 
cortex, hippocampus, striatum, or cerebellum that were incubated with 300 nM [3H] 
lacosamide. To maximize CRMP2 levels, fractions were taken from CRMP2-expressing 
oocytes and incubated with 969 nM [3H] lacosamide. Still, no specific binding was 
observed. CRMP2 expressed in Cos-7 cells was sequestered by coupling to SPA beads prior 
to incubation with 600 nM [3H] lacosamide. Again, no specific binding was reported. 
Ultimately, surface plasmon resonance (SPR) was employed to address binding between 
immobilized CRMP2 and lacosamide. SPR monitors changes in resonance angle of light off 
a surface as a direct result of changes in the refraction index of the surface. Ligands 
(lacosamide) interacting the proteins (CRMP2) immobilized onto the surface alters the 
refraction index of the surface which is detected through changes in the light’s resonance 
angle (for review see [51,52]). SPR studies revealed no detectable interaction between 
immobilized CRMP2 and lacosamide, ranging in concentration from 0.39–100 μM. 
However, due to the harsh conditions required for the immobilization process, it is necessary 
to demonstrate functionality of the protein before lack of binding can be verified. Also, 
availability of the binding site must also be considered. While the immobilized protein 
should exist in a variety of confirmations, there is a slight possibility that one orientation is 
energetically favored, resulting in the majority of the immobilized protein in one 
confirmation. For these reasons, the use of SPR to confirm lack of binding is considered 
controversial. Based on the lack of specific binding in this report, the authors infer that any 
effects of lacosamide on CRMP2, or vice versa, must be indirect in nature. The authors 
suggest that results gleaned from affinity bait studies do not provide direct evidence that 
CRMP2 is a target of lacosamide. As the structure of the ligand required modification 
(addition of AB and CR moieties), the observed interaction may be a result of an altered 
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receptor interaction profile and may not be reflective of interactions between the parent 
compound and the proposed target.
Recently, our laboratory has employed the novel technique of microscale thermophoresis 
(MST) to investigate potential binding between lacosamide and CRMP2. MST employs the 
movement of proteins induced by microscopic temperature gradients to measure interactions 
between ligands and target proteins. This movement is determined by the entropy of the 
hydration shell surrounding the target protein. Binding of other proteins, peptides, or small 
molecules alters the hydration shell, resulting in a change in thermophoretic movement that 
is visualized as a change in fluorescence [53] (Figure 2A). Primary-amine labeled CRMP2 
or CRMP25ALA were incubated with varying concentrations of lacosamide (0.009–150 μM 
and 0.03–1000 μM, respectively). Standard capillaries (Monolith NT Capillaries, 
NanoTemper) were filled with ~5 μl of sample mixture and thermophoresis analysis was 
performed on a NanoTemper Monolith NT.115 instrument. MST curves were fitted using 
GraphPad Prism software to obtain relative Kd values. Thermophoresis of labeled CRMP2 
was altered by increasing concentrations of lacosamide, indicating an interaction with Kd 
value of 1 ± 0.04 μM (Figure 2B–C). Thermophoresis of labeled CRMP25ALA was not 
affected by lacosamide, even at concentrations as high as 1 mM (Figure 2D–F). The lack of 
association with CRMP25ALA suggests both that the ability of lacosamide to alter 
thermophoresis of wildtype CRMP2 is not due to non-specific binding and that the 
interaction between lacosamide and CRMP2 is coordinated by the binding pockets 
previously identified via in silico docking.
While the MST results provide strong evidence in support of a direct interaction between 
lacosamide and CRMP2, more research is needed in order to definitively conclude the 
nature of the interaction, such as irreversibility and dynamics. However, the ability of 
lacosamide to impair neurite outgrowth and, more specifically, tubulin polymerization 
induced by wildtype but not mutant CRMP2 provides very strong evidence that lacosamide 
directly impairs CRMP2 function, irrespective of the nature of the physical interaction. The 
question remains as to what therapeutic impact this interaction may have. The majority of 
approved anti-epileptic drugs are effective at treating the symptoms of epilepsy, yet cannot 
be considered “disease modifying” as they do not directly impede disease progression. 
Partial-onset seizures are associated with acquired epilepsy as they often develop as a direct 
result of CNS trauma, such as stroke, traumatic brain injury (TBI), infections, or tumors 
[54]. Unfortunately, the mechanisms underlying epileptogenesis, particularly in acquired 
epilepsies, are not well understood.
Therapeutic potential of an interaction between CRMP2 and lacosamide
One hallmark of acquired epilepsy is the presence of a potentially months-long 
asymptomatic latent period between the instigating injury and the development of 
spontaneous recurrent seizures. This latent period provides a unique opportunity for 
prophylactic intervention if therapeutic targets were to be identified. Animal models have 
revealed significant morphological changes occurring during this period, which may be 
attributed to the development of epilepsy. One of the more striking changes is aberrant 
sprouting of axons in response to injury, which has been observed both in the hippocampus 
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and the neocortex in a variety of models [55–57]. Sprouting of injured axon fibers is 
associated with the formation of recurrent excitatory circuits [58], which directly contribute 
to the development of spontaneous seizure activity [59,60]. Robust axon sprouting and 
elongation has also been observed following in vitro lesion of axon collaterals and is 
sufficient to induce hyperexcitability and increased polysynaptic, epileptiform burst 
discharges [61]. A previous study of post-mortem tissue samples from patients with mesial 
temporal lobe epilepsy observed a decrease in a 55 kDa band associated with CRMP2, 
without a change in the higher molecular weight band [62]. It is now known that as the two 
splice variants of CRMP2 are expressed at 75- and 64 kDa [63], the 55 kDa band likely 
reflects a calpain-mediated breakdown product of CRMP2 [64]. What will be of particular 
interest are potential changes in phosphorylation state within the hippocampus of temporal 
lobe epilepsy patients, as the ability of CRMP2 to mediate neurite outgrowth is regulated via 
numerous phosphorylation events [65–67,30,25,27,68–70]. Indeed, changes in 
phosphorylation of CRMP2 have been observed following traumatic events often associated 
with the development of temporal lobe epilepsy, such as hypoxia-ischemia and TBI [71,72]. 
Interestingly, recent work has linked the sprouting of mossy fibers in the hippocampus 
following status epilepticus with CRMP2 [73]. The ability of lacosamide to target not only 
sodium channel activity, but CRMP2-mediated synaptic reorganization as well, may afford 
efficacy in the prevention of epileptogenesis, where so many classical antiepileptics have 
failed. However, the anti-epileptogenic potential of lacosamide relies heavily on the 
assumption that the relationship between aberrant sprouting and epileptogenesis is causal in 
nature.
Work by Brandt and colleagues demonstrated that lacosamide treatment could hinder the 
progression of kindling [74], a model often used to investigate mechanisms of 
epileptogenesis (for review see [75]). As the majority of AEDs are not disease-modifying, 
they do not alter kindling acquisition (for review see [76]). Rats were kindled by once-daily 
stimulation of the amygdala 0.5 hrs following intra-peritoneal injection of 3, 10, or 30 mg/kg 
lacosamide. Both the severity of seizures and duration of after-discharges elicited by each 
current injection were decreased in animals treated with 10 or 30 mg/kg lacosamide. 
Additionally, lacosamide treatment led to a ~90% increase in the number of stimulations 
required for kindling. In fact, while all of the vehicle-treated rats were successfully kindled, 
kindling in the 10 and 30 mg/kg treatment groups was unsuccessful in 2/10 and 3/10 rats, 
respectively. To determine if the effect of lacosamide was long-lasting, after 22–23 days of 
stimulation rats were allowed a 2.5 month washout period, during which they received no 
current injections. All rats could be rekindled within 4 stimulations, regardless of prior 
lacosamide treatment. This outcome can be explained in a variety of ways. Of the rats used 
for the washout experiments, 7/10 lacosamide treated rats and 10/10 vehicle treated rats had 
reached kindled status, which by definition insinuates that all rats underwent class V 
seizures in response to the same current injection. Therefore, as the seizure severity was 
relatively conserved across treatment groups in the presence of treatment, differences 
following a treatment-free washout period were unlikely. For this reason, previous work 
involving washout periods following amygdala stimulations excluded animals which had 
reached kindled status prior to washout [77]. In these studies, which identified potential anti-
epileptogenic properties of the AED levetiracetam, the rate of kindling following washout 
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was slower in previously exposed animals. Once kindling was obtained, however, focal 
seizure threshold was not different from controls. Therefore it is possible that while the 
kindling model provides a framework for anti-epileptogenic intervention, once kindling 
status has been reached the opportunity for prophylaxis may have passed. Alternatively, as 
lacosamide is now known to lower excitability by enhancing sodium channel slow-
inactivation, treatment directly prior to stimulation may have simply dampened the response 
to the current injections, thereby impeding the kindling process.
Aside from kindling, models involving spontaneous recurring seizures following sustained 
status epilepticus (SE) in rodents have been extensively used to evaluate anti-epileptogenic 
potential of therapeutic agents. Animals were given a single dose of lacosamide, 10 minutes 
following initiation of perforant path stimulation, which lasted 30 minutes. Lacosamide 
treatment was associated with a dose-dependent decrease in the number of spontaneous 
recurrent seizures (SRS) 6 weeks following induction of status epilepticus [78]. As the 
development of SRS is dependent upon successful, sustained status epilepticus, it is possible 
that the reduction of seizures is a direct result of lacosamide interfering with the induction 
process. Therefore, a second group of animals received lacosamide treatment 40 minutes 
following perforant path stimulation. While all of the vehicle-treated animals demonstrated 
SRS, they were only observed in 3 of 9 lacosamide-treated animals. Interestingly, of the 
animals that did develop SRS, there was no difference in the number of seizures across 
groups, suggesting that the development of SRS may be an all or nothing process. That late 
lacosamide treatment was able to prevent the development of SRS in 6 of 9 animals suggests 
that lacosamide may have some anti-epileptogenic potential. Although its direct role in 
epileptogenesis has not been confirmed, extensive mossy fiber sprouting occurs following 
SE and has been linked to changes in CRMP2 function [73]. Our laboratory recently 
employed the undercut (neocortical isolation) model of post-traumatic epileptogenesis to 
explore the ability of lacosamide to alter CRMP2-mediated changes in excitatory 
connectivity [49]. In this model of posttraumatic epileptogenesis, axon sprouting has been 
demonstrated by morphological reconstruction of axons of the layer V pyramidal neurons 
[55] and by functional mapping of excitatory synaptic connectivity using laser scanning 
photostimulation of caged glutamate [58]. Animals received daily lacosamide treatments for 
1 week following surgery, upon which time the animals were allowed to an additional week. 
While field potential recordings did not reveal a difference in the frequency of evoked 
epileptiform events, the mean amplitude of the recordings was significantly lower in 
lacosamide treated animals. Importantly, electrophysiological recordings from layer V 
pyramidal neurons revealed a decrease in the frequency of spontaneous excitatory post-
synaptic currents. A decrease in frequency without a change in the amplitude or kinetics 
(rise time, decay time, constant, and ½ width of events) is indicative of a decrease in the 
number of synaptic connections. Indeed glutamate uncaging studies demonstrated a decrease 
in excitatory connectivity following lacosamide treatment. As animals had undergone a 1-
week washout period prior to all recordings, these results suggest that lacosamide may have 
had a disease-modifying effect following neocortical isolation.
As previously mentioned, traumatic brain injury is a common instigator of acquired 
epilepsy. Mice receiving closed-head TBI were treated with lacosamide 30 minutes 
following injury and continuing twice daily for 3 days. Lacosamide treatment was associated 
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with a decrease in neuronal injury that was correlated by a delay in the expression of pro-
inflammatory mediator genes and reduced microglial activation [79]. Lacosamide-treated 
mice demonstrated improved function in both the rotorod and Morris water maze paradigms. 
Interestingly, contrary to previous reports that CRMP2 activity is important in mossy fiber 
sprouting and that lacosamide can impact CRMP2 function, the emergence of mossy fiber 
projections into the inner molecular layer was not altered by lacosamide treatment. 
However, mossy fiber sprouting is viewed as a progressive process and is typically 
measured in much later stages following injury. It would be interesting to extend treatment 
well into the latent period when mossy fiber sprouting is at its highest. In a recent study of 
rats exposed to the lateral fluid percussion model of TBI, however, lacosamide given at 30 
min post-injury and continued at 8 hr intervals for 3 days had no effect on neuroscore, beam 
walking, or water maze performance [80]. Furthermore, histological analysis revealed no 
difference in the extent of neurodegeneration, axonal injury, or hilar neuron loss within the 
hippocampus of lacosamide-treated rats compared to vehicle treatment. Recently, Licko and 
colleagues sought to expand previous reports on the anti-epileptogenic potential of 
lacosamide following status epilepticus [81]. To avoid any possible interference with the 
induction of sustained SE, lacosamide treatment began following its cessation and was 
continued for 23 days. On the molecular level, many hallmarks associated with status 
epilepticus were altered by lacosamide treatment. Chronic lacosamide treatment prevented 
both neurogenesis of granule neurons as well as cell loss within the piriform cortex and CA1 
region of the hippocampus yet did not impede the aberrant migration of neurons into the 
hilus. Unfortunately, the extent of mossy fiber sprouting was not determined in this report. 
However, lacosamide treatment was associated with a decrease in the number of SE-induced 
persistent basal dendrites present in the hilar region. Despite the impact on molecular 
changes induced by SE and contrary to previous reports, lacosamide treatment did not 
successfully prevent the development of SRS. Additionally, latency to first seizure and the 
frequency of spontaneous seizures were not attenuated by chronic lacosamide treatment 
[81]. While the treatment paradigm was somewhat unorthodox, combining oral 
administration and continuous infusion via osmotic minipump, it is unlikely that this would 
account for the lack of efficacy in preventing the development of spontaneous seizures. In 
light of all the aforementioned work in vivo, it is difficult to determine whether lacosamide 
is anti-epileptogenic in nature.
Combined in vivo results suggest that lacosamide may have potential as a disease-modifying 
AED; however, more work is needed in 2 critical areas: (1) It is necessary to determine 
whether lacosamide prevents aberrant sprouting, such as that of mossy fibers within the 
hippocampus, in multiple of models of acquired epilepsy. While it is likely that there are 
common mechanisms involved in aberrant sprouting induced by different insults, even slight 
disparities may account for incongruous reports using different models. It is important not to 
dismiss the therapeutic potential of a compound based on the results from one model alone, 
especially as it is unclear which model most directly mimics the human condition. (2) Is 
preventing aberrant sprouting sufficient to prevent epileptogenesis? The relationship 
between epileptogenesis and circuit reorganization is still highly debated. In theory, the 
formation of recurrent excitatory circuits should increase excitability and decrease the 
threshold for spontaneous epileptiform events [82]. However, recent work by the 
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Buckmaster group has demonstrated the ability to attenuate mossy fiber sprouting without 
impacting seizure frequency following status epilepticus in mice [83]. While the results 
suggest a disconnect between mossy fiber sprouting and epileptogenesis, the authors advise 
that rapamycin, at the doses required to completely block mossy fiber sprouting, has many 
other effects. According to the authors, some of these effects may be pro-epileptogenic in 
nature, thereby canceling out any potential anti-epileptogenic effect that the prevention of 
mossy fiber sprouting may carry. Therefore, we still cannot definitively identify the exact 
role of mossy fiber sprouting without more selective means.
Additionally, as CRMP2 is also involved with important developmental processes such as 
neuronal migration and polarity, we must also consider the potential negative impact of 
targeting CRMP2 in pediatric patients. Despite these concerns, however, the safety profile of 
lacosamide in children is reminiscent of that in adults [84]. In fact, lacosamide has recently 
shown promising potential in the treatment of refractory focal epilepsy with high tolerability 
in two separate reports utilizing patient populations with a median age of 13.9 and 2.7 years 
[85,86]. Nevertheless, limited data is available for the long-terms effects of lacosamide 
treatment in pediatric patients or those exposed prenatally [87]. Given the role of neurite 
outgrowth in neuronal plasticity, of particular interest will be the long-term impact of 
lacosamide treatment on learning and memory.
Conclusion
Here we have addressed two controversial issues surrounding the novel anti-epileptic drug 
lacosamide. First, is CRMP2 a bona fide target of lacosamide? Second, does lacosamide’s 
proposed dual mode of action provide disease-modifying properties? Unfortunately, direct 
answers exist for neither of these issues. However, new data presented here of a specific 
association between lacosamide and CRMP2 in solution, in combination with previous 
reports of a direct impact on CRMP2 function, provide strong evidence in support of a direct 
interaction between lacosamide and CRMP2. Future work should seek to address the 
disease-modifying potential of lacosamide. Given the two distinct mechanisms through 
which lacosamide may impact epileptogenesis (hyperexcitability via the VGSC and circuit 
reorganization via CRMP2) it would be of great interest to dissect out the individual 
importance of each on the full mechanism of action of lacosamide. Additionally, 
understanding the molecular and mechanistic framework for lacosamide’s actions on 
CRMP2 will consolidate the involvement of CRMP2 as a potentially important player in 
neuropathology and as a novel drug target for epilepsy.
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Figure 1. Affinity bait capture of lacosamide-interacting proteins
Lacosamide compounds modified to contain affinity bait (AB) and chemical reporter (CR) 
moieties. Capture and covalent modification of interaction targets occurs at the AB site. 
Addition of the CR site allows for the isolation (via biotin) or detection (via fluorescence) of 
the captured complex. Adapted with permission from Park and colleagues [88].
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Figure 2. Binding of lacosamide ((R)-LCM) to wildtype but not mutant CRMP2 in solution
(A) Representative microscale thermophoresis (MST) curve. A standard capillary containing 
NT647-labeled protein is locally heated by an IR laser (green arrow). Labeled protein 
diffuses away from the heated spot, causing a local depletion and drop in fluorescence. 
Fluorescence returns following cessation of the IR laser (red arrow). Dashed yellow lines 
indicate the point at which the degree of thermodiffusion is measured. (B). MST time traces 
of wildtype CRMP2 and (R)-LCM (0.009–150 μM). Thermodiffusion of CRMP2 was 
altered by increasing concentrations of (R)-LCM. (C) Logarithmic concentration-response 
curve used to determine the dissociation constant of (R)-LCM to fluorescently labeled 
CRMP2. Values represent mean ± SEM from 3 separate trials. (D) CRMP2 surface 
representation highlighting the location of the (R)-LCM binding pocket (green). The box 
represents an enlarged view of the binding pocket highlighting the helices and beta-strands 
(gold) involved in coordinating (R)-LCM binding. The mutated residues comprising 
CRMP25ALA are indicated in single amino acid letter code. (E) MST time traces of 
CRMP25ALA and (R)-LCM (0.030–1000 μM). Thermodiffusion of CRMP25ALA was not 
altered by increasing concentrations of (R)-LCM. (F) Logarithmic concentration-response 
curve further demonstrates that (R)-LCM does not interact with CRMP25ALA.
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Figure 3. Mechanisms through which lacosamide (LCM) may provide disease-modifying effects
Enhancement of sodium channel slow inactivation leads to a decrease in the fraction of 
available voltage-gated sodium channels. Through this mechanism, LCM is able to hinder 
epileptiform activity. Inhibition of CRMP2-mediated tubulin polymerization may attenuate 
the aberrant circuit reorganization commonly observed within the epileptic hippocampus 
and neocortex. While the exact contribution of this reorganization to epileptogenesis is not 
yet fully understood, it is possible that the two functions of lacosamide may provide the 
ability to affect disease progression.
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